Skip to main navigation

Overview
News & Events
Financials & Filings
- Overview
- All SEC Filings
Corporate Governance
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources

ZyVersa in the News

ZyVersa in the News

Year

ZyVersa’s inflammasome inhibitor shown to address key hallmarks of Parkinson’s disease pathology – inflammation and protein misfolding.

April 29, 2025

ZyVersa Therapeutics Unveils Groundbreaking Research on Targeting ASC Specks in Alzheimer's Disease

February 24, 2024

BioTuesdays Featured Article: ZyVersa developing multiple drug therapies in renal, inflammatory diseases

June 13, 2023

Inflammatory protein ASC may be therapeutic target in Parkinson’s

May 16, 2023

New findings on brain electrodes might improve deep brain stimulation in Parkinson’s Disease

April 24, 2023

New Research Finds Antibody Detects Alzheimer’s Signals at Earliest Stages

March 14, 2023

Meet ZyVersa: Fly Exclusive Interview with CEO Stephen Glover

January 12, 2023

Changing Lives Through the Power of Technology

February 1, 2020

Kidney is the new liver: why kidney indications are coming into sharp focus

October 3, 2019

Developing Innovative Drug Therapies for Patients with Inflammatory and Renal Diseases

September 23, 2019

Current page 1
Page 2
Next page
Last page

About
Inflammasomes
Renal Lipids
Pipeline
Careers
Investors & Media
Contact

©2026 ZyVersa Therapeutics, Inc. All rights reserved.

Privacy Policy
Disclaimer
Trademarks
Sitemap